Clinical Trials Sponsored by Idorsia Pharmaceuticals Ltd.

Total 4355 results

Idorsia Pharmaceuticals Ltd.

Recruiting

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS-1)

Lupus Erythematosus, Systemic

Taiwan, United States, Korea, Republic of, Poland, Greece, Philippines, Romania, Bulgaria, Argentina, France, Mexico
Idorsia Pharmaceuticals Ltd.

Recruiting

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

Insomnia

Spain, United States, Belgium, Germany, Bulgaria
Idorsia Pharmaceuticals Ltd.

Recruiting

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

Healthy | Hepatic Impairment

Portugal, Hungary
Idorsia Pharmaceuticals Ltd.

Active, not recruiting

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Fabry Disease

United States, United Kingdom, Norway, Germany, Australia, Canada, Spain, Switzerland, Austria, Belgium, France, Netherlands, Poland
Idorsia Pharmaceuticals Ltd.

Completed

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

Healthy | Renal Impairment

Portugal
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics

Healthy Subjects | Hepatic Impairment

Germany
Idorsia Pharmaceuticals Ltd.

Completed

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

Healthy Subjects

France
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects

Healthy

Portugal
Idorsia Pharmaceuticals Ltd.

Completed

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

Healthy | Renal Insufficiency

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Healthy Volunteers

United States
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Belarus, Bulgaria, Georgia, Russian Federation, Ukraine
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Idorsia Pharmaceuticals Ltd.

Completed

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

Insomnia Disorder

United States, Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate Whether Administration of Rifampicin Can Affect the Fate of Clazosentan in the Body of Clazosentan

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Essential Hypertension (REDUCE-1)

Essential Hypertension

Israel, Serbia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

Healthy Subjects

United States
Idorsia Pharmaceuticals Ltd.

Completed

Tezosentan in Acute Heart Failure (VERITAS 1)

Acute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart Failure

United States, United Kingdom, Israel, Switzerland, Austria, Denmark, France, Germany, Greece, Poland
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma (CONTROL)

Asthma

United States, Australia, Bulgaria, Germany, Hungary, Israel, Poland, Russian Federation, Serbia, Singapore, South Africa, Sweden, Ukraine
Idorsia Pharmaceuticals Ltd.

Completed

Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects

Healthy

United Kingdom
Idorsia Pharmaceuticals Ltd.

Recruiting

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

Lupus Erythematosus, Systemic

Spain, Serbia, Georgia, Germany, Portugal, Poland, South Africa, United States, Philippines, Czechia, Puerto Rico, Chile, Japan, Peru
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain (REACT)

Aneurysmal Subarachnoid Hemorrhage

United States, Spain, Israel, Finland, Poland, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Sweden
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Spain, United States, Italy, Taiwan, Thailand, Poland, Russian Federation, Israel, Ukraine, Mexico, Philippines, Georgia, United Kingdom, Chile, France, Bulgaria, Czechia, Greece, Hungary, Romania, Turkey, Germany, Puerto Rico, Japan
Idorsia Pharmaceuticals Ltd.

Completed

A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep

Obstructive Sleep Apnea of Adult

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Male Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects

Healthy Subjects

Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

Healthy Subjects

United States
Idorsia Pharmaceuticals Ltd.

Completed

The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

Healthy Subjects | Hepatic Impairment

Germany, Poland
Idorsia Pharmaceuticals Ltd.

Completed

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

Essential Hypertension

United States, Canada, Israel, Puerto Rico
Idorsia Pharmaceuticals Ltd.

Completed

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Stable Coronary Artery Disease

Denmark, Netherlands, Singapore, Canada, United Kingdom, United States, Germany, Sweden
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

Healthy Subject

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects

Healthy Subjects

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects

Healthy

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis

Bilateral Nasal Polyposis

Germany, Belgium
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Insomnia Disorder

United States, Germany, Canada, Denmark, Poland, Spain, Switzerland, Belgium, Bulgaria, Finland, France, Hungary, Korea, Republic of, Sweden
Idorsia Pharmaceuticals Ltd.

Completed

Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2 (RETRIEVE)

GM2 Gangliosidosis | GM1 Gangliosidosis | Tay-Sachs Disease | Sandhoff Disease | Gaucher Disease, Type 2 | AB Variant Gangliosidosis GM2

United States, Spain, Germany, Italy, Belgium, Brazil, France, Portugal, Switzerland, United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland

3

Subscribe